Key points are not available for this paper at this time.
Design
Editorial
This commentary contextualizes findings that anti-β1-adrenergic receptor antibodies directly cause cardiomyopathy, reinforcing the mechanistic rationale for beta-blocker therapy in heart failure.
Antibodies specific for the 1 -adrenergic receptor are found in patients with chronic heart failure of various etiologies. From work presented in this issue of the JCI (see the related article beginning on page 1419), we can now infer that these antibodies actually contribute to the pathogenesis of chronic heart failure. This commentary discusses mechanisms by which these antibodies may engender cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Freedman et al. (2004) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: